Latest Tax Rebates News

BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.

PlaySide Studios reported a sharp 28% revenue decline for H1 FY26 but posted a remarkable 249% jump in profit, buoyed by cost cuts and a $7.8 million tax rebate. The company also secured a $6 million loan and inked a new global publishing deal.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

South Harz Potash Limited has made significant strides in its critical minerals strategy, securing new exploration licences in Sweden and uncovering promising copper, gold, and rare earth element mineralisation. The company also bolsters its leadership with a key board appointment as it prepares for a transformative 2026.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

FirstWave Cloud Technology has completed a $2.66 million capital raise alongside operational restructuring and a strategic shift to AI-powered compliance management, positioning itself for growth with renewed key contracts and improved cash flow.

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

FirstWave Cloud Technology Limited has completed a $2.66 million capital raise alongside an operational restructure, setting the stage for its strategic pivot to AI-powered compliance management. The company expects a cash-flow positive quarter ahead, supported by key contract renewals and anticipated R&D rebates.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

Mont Royal Resources has kicked off a comprehensive work program at its Ashram Rare Earth and Fluorspar Project following a transformative merger and a successful $10 million capital raise. An updated Preliminary Economic Assessment is expected by the end of Q1 2026.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.